TSVT vs. TELO, XERS, PBYI, ACIU, FHTX, HOWL, NBTX, AEON, VNDA, and PRLD
Should you be buying 2seventy bio stock or one of its competitors? The main competitors of 2seventy bio include Telomir Pharmaceuticals (TELO), Xeris Biopharma (XERS), Puma Biotechnology (PBYI), AC Immune (ACIU), Foghorn Therapeutics (FHTX), Werewolf Therapeutics (HOWL), Nanobiotix (NBTX), AEON Biopharma (AEON), Vanda Pharmaceuticals (VNDA), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical preparations" industry.
2seventy bio (NASDAQ:TSVT) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking.
In the previous week, 2seventy bio and 2seventy bio both had 1 articles in the media. 2seventy bio's average media sentiment score of 0.50 beat Telomir Pharmaceuticals' score of 0.00 indicating that 2seventy bio is being referred to more favorably in the media.
Telomir Pharmaceuticals has a net margin of 0.00% compared to 2seventy bio's net margin of -216.73%. Telomir Pharmaceuticals' return on equity of 0.00% beat 2seventy bio's return on equity.
93.9% of 2seventy bio shares are owned by institutional investors. 2.6% of 2seventy bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Telomir Pharmaceuticals has lower revenue, but higher earnings than 2seventy bio.
2seventy bio received 23 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users.
2seventy bio presently has a consensus target price of $13.17, indicating a potential upside of 204.78%. Given 2seventy bio's higher possible upside, equities analysts clearly believe 2seventy bio is more favorable than Telomir Pharmaceuticals.
Summary
2seventy bio beats Telomir Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
Get 2seventy bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TSVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
2seventy bio Competitors List
Related Companies and Tools
